🔗 Share this article

While America proceeds with sweeping changes to its immunization schedules, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by questioning COVID-19 vaccines in the global health crisis and has zeroed in on potential deaths following COVID-19 immunization in her brief tenure at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Vaccine Program

Health officials were set to announce major revisions to the childhood vaccination calendar in December, synchronizing the US with the Danish vaccine program, according to reports – a significant shift that would place the US at odds with a large portion of the international standard with no evidence for improved outcomes. The announcement has been postponed until the new year.

Instead of Vinay Prasad, Høeg is listed to speak at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this year.

A Shift at the Regulatory Body

The acting appointment might represent a closer partnership between the drug and vaccine divisions as Dr. Høeg and Prasad consolidate power at the agency – and it signals a increased emphasis upon rolling back previously authorized vaccines at the FDA.

The new acting director has frequently advocated for discontinuing certain pediatric immunization guidelines in the US in order to be more in line with Denmark, a country with universal health coverage and a population about the population of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccines – typically the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Expertise

Dr. Høeg has no apparent experience in drug development, approval processes or leadership, which has been standard for previous directors of the CBER. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“It seems she lacks to have the requisite experience” for running the CDER, said Jonathan Howard. “She’s never run a clinical trial. She is not versed in running a major agency. She has no expertise in industry regulation.”

Previous commissioners of CBER would “understand regulatory frameworks and the research of pharmaceutical innovation”, noted Janet Woodcock. “Clearly, she has not acquired the sort of resume that previous people who headed CBER have had.”

This division has an vast range of responsibilities at the agency, the former commissioner pointed out.

“The public just zeroes in on the novel medication approvals, but the generic program approves numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and other areas, and each of these have to be managed,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant management element to the job, which supervises over 5,000 personnel. “It’s a enormous administrative position, if you perform it correctly,” Woodcock said.

Agency Reaction and Contentious Policies

When asked about questions about Dr. Høeg's credentials and whether this appointment signifies more teamwork among FDA leaders on vaccines, a spokesperson said that the “questions stem from inaccurate presumptions”.

“Her resume matches the functions of her position,” the official stated, citing the months Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s controversial expedited review system, a disputed one-day medication authorization process that reportedly troubled her former heads. “How are these drugs being selected for this voucher program? Who makes the calls?” Dr. Howard said. “There is a lot of secrecy occurring at the FDA right now.”

Overall, he said, “the agency seems to be moving towards more relaxed rules of pharmaceuticals, with the exception of shots.”

Established Track Record on Vaccines

With vaccines, Dr. Høeg has a more documented, if problematic, history, some experts have noted. She published a study using unconfirmed crowd-sourced reports to assess the frequency of heart inflammation following COVID-19 immunization. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming government featured altering guidelines for recently developed shots and halting “unnecessary” immunizations, she said following the vote on a online show. At the agency, Høeg has allegedly floated the idea of excluding adolescent males from obtaining COVID-19 vaccines.

“She’s an thorough dogmatist who begins with her preconceived notions and works backwards to retrofit the data in a very deceptive, untruthful way,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Høeg aligned with other dissenters, {like|